{
    "clinical_study": {
        "@rank": "134492", 
        "arm_group": [
            {
                "arm_group_label": "1: MDV3100", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "2: MDV3100 and gemfibrozil", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "3: MDV3100 and itraconazole", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to assess possible drug-drug interactions between MDV3100 and gemfibrozil and\n      MDV3100 and Itraconazole."
        }, 
        "brief_title": "Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole", 
        "completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Subjects", 
            "Pharmacokinetics", 
            "Drug-Drug Interaction"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body weight of at least 65.0 kg and no greater than 85.0 kg.\n\n          -  Body Mass Index (BMI) of at least 18.5 and no greater than 30.0 kg/m2.\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to MDV3100, itraconazole, gemfibrozil, any\n             components of the formulations used, or any history of liver toxicity with other\n             drugs.\n\n          -  Confirmed CYP2C8 PM status based on genotyping analysis.\n\n          -  Any of the liver function tests above the upper limit of normal. A retest to confirm\n             the result may be performed once.\n\n          -  History of seizure, including any febrile seizure, loss of consciousness, or\n             transient ischemia attack within 12 months prior to enrollment (Day 1 visit), or any\n             condition that may pre-dispose to seizure (e.g., prior stroke, brain arteriovenous\n             malformation, head trauma with loss of consciousness requiring hospitalization).\n\n          -  Any clinically significant history of asthma, eczema, any other allergic condition or\n             previous severe hypersensitivity to any drug (excluding non-active hay fever).\n\n          -  Abnormal pulse and/or blood pressure (BP) measurements at the pre-study visit as\n             follows: Pulse <40 or >90 bpm; mean systolic BP >140 mmHg ; mean diastolic BP >90\n             mmHg (BP measurements taken in triplicate after subject has been resting in supine\n             position for 5 min; pulse will be measured automatically).\n\n          -  A QTc interval of >430 ms after repeated measurements (consistently after duplicate\n             measurements), a history of unexplained syncope, cardiac arrest, unexplained cardiac\n             arrhythmias or torsades de pointes, structural heart disease, or a family history of\n             Long QT Syndrome (LQTS).\n\n          -  Regular use of any inducer of metabolism (e.g. barbiturates, rifampin) in the 3\n             months prior to admission to the Clinical Unit.\n\n          -  Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "41", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913379", 
            "org_study_id": "9785-CL-0006", 
            "secondary_id": "2011-000333-37"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1: MDV3100", 
                    "2: MDV3100 and gemfibrozil", 
                    "3: MDV3100 and itraconazole"
                ], 
                "description": "Oral", 
                "intervention_name": "MDV3100", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ASP9785", 
                    "Xtandi", 
                    "enzalutamide"
                ]
            }, 
            {
                "arm_group_label": "2: MDV3100 and gemfibrozil", 
                "description": "Oral", 
                "intervention_name": "Gemfibrozil", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "3: MDV3100 and itraconazole", 
                "description": "Oral", 
                "intervention_name": "Itraconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemfibrozil", 
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "MDV3100", 
            "Gemfibrozil", 
            "Itraconazole", 
            "Xtandi", 
            "enzalutamide"
        ], 
        "lastchanged_date": "July 30, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75015"
                }, 
                "name": "SGS"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I Randomized, Open-label, 3-arm Parallel-design Study to Determine the Effect of Multiple-dose Gemfibrozil or Itraconazole on the Pharmacokinetics, Safety and Tolerability of Single-dose MDV3100 (ASP9785) in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe B.V.", 
            "last_name": "Operation Senior Research Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Assessment of pharmacokinetic profile of MDV3100 by Cmax (Maximum concentration)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 53 (29 times)"
            }, 
            {
                "measure": "Assessment of pharmacokinetic profile of MDV3100 by AUCinf  (AUC extrapolated to infinity)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 53 (29 times)"
            }, 
            {
                "measure": "Assessment of pharmacokinetic profile of MDV3100 by AUC0-432h (AUC from the time of dosing to 432 hours post-dose)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 53 (29 times)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913379"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "tmax (Time to attain Cmax), t1/2 (Apparent terminal elimination half life), Vz/F (Apparent volume of distribution during the terminal phase after extra vascular dosing) and CL/F(Apparent total body clearance after extra vascular dosing)", 
                "measure": "Assessment of pharmacokinetic profile of MDV3100", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 53 (29 times)"
            }, 
            {
                "description": "Cmax, AUC0-432h, tmax, t1/2, and AUC0-inf", 
                "measure": "Assessment of pharmacokinetic profile of the metabolites MDPC0001 and MDPC0002", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 53 (29 times)"
            }, 
            {
                "description": "This may additionally be reported  to assess effects on particular enzyme pathways", 
                "measure": "Assessment of metabolite-to-parent ratios for MDV3100", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 53 (29 times)"
            }, 
            {
                "description": "Cmax, C0h, Cmin, tmax, AUCtau", 
                "measure": "Assessment of Gemfibrozil and gemfibrozil 1-O-\u03b2-glucuronide (Arm 2)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 53 (50 times)"
            }, 
            {
                "description": "Cmax, C0h, Cmin, tmax, AUCtau", 
                "measure": "Assessment of itraconazole and hydroxyitraconazole (Arm 3)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 53 (50 times)"
            }, 
            {
                "description": "In arm 3, liver function tests (AST, ALT, GGT, total bilirubin) will be done regularly during itraconazole dosing", 
                "measure": "Safety as assessed by recording adverse events, laboratory assessments, vital signs and electrocardiograms (ECGs)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 53"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Medivation, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}